Top 100 Most Prescribed, Top Selling Drugs
(Registration required, but free.) Article from Medscape Medical News. These are the Amgen medications on the list:
Editor's note: With $14.2 billion in revenues per year from these medications alone, is it any wonder that Amgen is able to effectively control dialysis-related legislation and the nephrology/ESRD-industrial complex?
- #6 Enbrel, arthritis drug; $4,896,267,318
- #10 Neulasta, stimulates WBC production, $3,634,919,067
- #20 Epogen, ESA, $2,346,224,521
- #58 Neupogen, stimulates WBC production, $944,389,150
- #69 Sensipar, calcimimetic, $824,871,721
- #70 Xgeva, antibody for bone disorders, $822,603,435
- #73 Aranesp, ESA, $814,017,366
This is mostly taxpayer/Medicare money. Amgen's profit margins on ESAs are over 90%. Congress takes its share for campaign financing. And who in this field doesn't take Amgen money? It buys an unholy silence.
I believe in rewarding risk taking, but Amgen has simply used legal and business strategies to soak American taxpayers for decades. Its control of the legislative process also keeps thousands of low-income patients on dialysis and using Amgen's drugs.